AstraZeneca (AZN)
(Delayed Data from NSDQ)
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.16 USD
+0.27 (0.33%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $81.11 -0.05 (-0.06%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication
by Zacks Equity Research
AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.
Roche's (RHHBY) Application for PNH Drug Accepted by FDA
by Zacks Equity Research
Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.
Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock
by Zacks Equity Research
Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
by Zacks Equity Research
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Medicare's First Price Negotiation List Targets Expensive Drugs
by Kinjel Shah
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca
by Zacks Equity Research
Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.
Oncology Market's Huge Potential Puts These Stocks in Focus
by Sanghamitra Saha
The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.
AstraZeneca's (AZN) Lynparza Gets Expanded Use Nod in Japan
by Zacks Equity Research
AstraZeneca (AZN) gets approval for Lynparza with abiraterone and prednisolone combo in Japan to treat adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.
Emergent BioSolutions (EBS) Down 12% in a Week: Here's Why
by Zacks Equity Research
Shares of Emergent (EBS) are on a downward trajectory since the ticker was dropped from the S&P SmallCap 600 index.
Pfizer's (PFE) RSV Vaccine Abrysvo Gets Approval in EU
by Zacks Equity Research
Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.
Pharma Stock Roundup: PFE Gets Nod for RSV Vaccine, J&J Finalizes Kenvue Separation
by Kinjel Shah
FDA and EU approve Pfizer's (PFE) RSV vaccine, Abrysvo for maternal immunization. J&J (JNJ) finalizes separation of its Consumer Health company, Kenvue.
Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.
Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
by Zacks Equity Research
Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
Apellis (APLS) Focuses on Empaveli to Fuel Its Growth
by Zacks Equity Research
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.
Is Most-Watched Stock AstraZeneca PLC (AZN) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
by Zacks Equity Research
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
by Zacks Equity Research
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.
Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View
by Zacks Equity Research
Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.
Company News for Jul 31, 2023
by Zacks Equity Research
Companies in The News Are: XOM, INTC, PG, AZN
AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales
by Zacks Equity Research
AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.